A 66-year-old Caucasian female was referred for specialist follow-up of her treatment-refractory type 2 diabetes. The diagnosis was made based on two consecutive HbA 1c results .6.5% (48 mmol/mol) in accordance with the Canadian Diabetes Association and the American Diabetes Association guidelines (1,2). Fasting glucose was normal and hyperglycemic symptoms were absent at diagnosis. The patient's hematological indices were normal and she was unaware of any family history of hemoglobinopathy. Her glycemic control proved difficult to manage, with persistently elevated HbA 1c (10.8-11.2% [95-99 mmol/mol]) despite treatment with metformin and, eventually, insulin glargine. Further, with treatment, the patient began to experience symptoms of episodic hypoglycemia.
The ordering physician was contacted and treatment withheld. The patient's blood glucose remained within normal limits with cessation of hypoglycemic symptoms. Hemoglobinopathy investigation revealed the presence of the a-globin chain mutant hemoglobin (Hb) Wayne. Carriers of one affected a-globin gene (aa/aa Wayne ) are clinically normal with unremarkable hematological indices (3). Hb Wayne was previously reported to interfere with Bio-Rad VARIANT II HPLC HbA 1c measurements (4 Clinical practice guidelines recommend repeat testing by the same method to confirm a diagnosis of type 2 diabetes in asymptomatic patients. This approach led to diabetes misdiagnosis in this patient despite the availability of additional laboratory tests, such as fasting glucose. With this case, we aim to highlight that despite the usefulness of practice guidelines, their limitations must be recognized and sound clinical judgment should prevail. Like all laboratory tests, HbA 1c measurement is subject to interferences, and results must be interpreted within the clinical context.
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